Neha Shah
Co-founder and CEO
Senticell
Liquid biopsy using red cell-bound nucleic acids
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Senticell is a Philadelphia biotechnology company developing liquid biopsy diagnostics based on red blood cell (RBC)-bound nucleic acids, aiming to surface disease signals that plasma-based approaches may miss. Built on University of Pennsylvania research with an exclusive license to its foundational RBC platform; initial focus includes oncology and infectious disease programs. Co-founded by Neha Shah (CEO) and Dr. Nilam Mangalmurti. Website: https://www.senticell.bio/.
- Website
- senticell.bio
- Stage
- seed
- Location
- Philadelphia, PA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Senticell RBC Liquid Biopsy Platform — RBC-bound nucleic acid diagnostics for earlier detection · Other
Founders
Nilam Mangalmurti
Co-founder and Chief Scientific Advisor